Indivior (NASDAQ:INDV) PT Lowered to $24.00

Indivior (NASDAQ:INDV) had its target price dropped by Craig Hallum from $37.00 to $24.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Craig Hallum’s target price would indicate a potential upside of 111.83% from the company’s current price.

Indivior Price Performance

Indivior stock opened at $11.33 on Wednesday. The company’s 50 day simple moving average is $16.55 and its 200-day simple moving average is $17.96. The company has a market capitalization of $1.56 billion, a price-to-earnings ratio of 1,133.00 and a beta of 0.69. Indivior has a 1 year low of $9.14 and a 1 year high of $24.90. The company has a debt-to-equity ratio of 23.50, a quick ratio of 0.74 and a current ratio of 0.92.

Indivior (NASDAQ:INDV) last released its quarterly earnings results on Thursday, April 25th. The company reported $0.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.01). The company had revenue of $284.00 million during the quarter, compared to analysts’ expectations of $300.00 million. Indivior had a net margin of 0.44% and a return on equity of 842.72%. As a group, equities research analysts expect that Indivior will post 1.93 earnings per share for the current year.

Institutional Investors Weigh In On Indivior

A number of institutional investors and hedge funds have recently made changes to their positions in INDV. Chilton Investment Co. Inc. acquired a new position in shares of Indivior in the fourth quarter valued at approximately $263,000. ADAR1 Capital Management LLC acquired a new position in shares of Indivior in the fourth quarter valued at approximately $368,000. Cannon Global Investment Management LLC acquired a new position in shares of Indivior in the first quarter valued at approximately $563,000. Forsta AP Fonden acquired a new position in shares of Indivior in the first quarter valued at approximately $641,000. Finally, Campbell & CO Investment Adviser LLC grew its holdings in shares of Indivior by 2.8% in the fourth quarter. Campbell & CO Investment Adviser LLC now owns 37,948 shares of the company’s stock valued at $573,000 after purchasing an additional 1,037 shares in the last quarter. 60.33% of the stock is owned by hedge funds and other institutional investors.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.